Comparative Pharmacology
Head-to-head clinical analysis: PHENYLBUTAZONE versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLBUTAZONE versus TAB PROFEN.
PHENYLBUTAZONE vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
NSAID
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."